Medicinova Inc (MNOV)
NASDAQ: MNOVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MNOV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $67.11M
- EPS (TTM)
- -$0.21
- Dividend yield
- None
- 52-week range
- 1.22 – 3.90
- Day range
- 1.27 – 1.31
- Volume / Avg
- 48.97K / 334.96K
- Beta
- —
- Shares outstanding
- 51.23M
52-week range
MNOV stock today
Medicinova (MNOV) closed at $1.31 on Nov 20, up 3.15% (+$0.04), versus the S&P 500's 3.70% decline. Trading was light, with 48.97K shares changing hands, about 15% of the average daily volume. At this level, MNOV sits near the bottom of its 52-week range of $1.22 to $3.90: 66.4% below the high, set on Sep 17, 2026 and 7.4% above the low.
MNOV is up 0.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.4%. Medicinova has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Medicinova
Company profileMediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Yuichi Iwaki M.D., Ph.D.
- Headquarters
- La Jolla, CA
- Employees
- 6
- Website
- medicinova.com
Financial highlights
Full financialsIn fiscal 2025, Medicinova generated $409,657 in revenue. Medicinova reported a net loss of $12.0 million, compared with a loss of $11.0 million a year earlier. Operating margin was -3242.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $409.66K | — | $1.00M | — | $4.04M |
| Growth | — | — | — | — | — |
| Net income | $-12.00M | $-11.05M | $-8.57M | $-14.07M | $-10.13M |
| EPS (diluted) | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$8.25+529.77%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.06 vs $-0.06
- Surprise
- 0.00%
MNOV news
All MNOV newsMedicinova peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs MNOV |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs MNOV |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs MNOV |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs MNOV |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs MNOV |
| COYACoya Therapeutics Inc. | 2.95 | -1.01% | $69.20M | vs MNOV |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs MNOV |
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.48 | -2.63% | $70.14M | vs MNOV |
Indexes, lists and sector
Medicinova stock FAQ
What is Medicinova's stock price today?
MNOV last traded at $1.31 as of Nov 20, 4:00 PM EST, up 3.15% on the day. Prices are delayed at least 15 minutes.
Who is Medicinova's CEO?
Dr. Yuichi Iwaki M.D., Ph.D. is the chief executive officer of Medicinova Inc, which has about 6 employees.
What is the MNOV 52-week high?
The 52-week high for MNOV is $3.90 and the 52-week low is $1.22. The stock is currently 66.4% below its high.